




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

COVID-19 – Considerations for the paediatric rheumatologist

Christian M. Hedrich



PII: S1521-6616(20)30259-X

DOI: <https://doi.org/10.1016/j.clim.2020.108420>

Reference: YCLIM 108420

To appear in: *Clinical Immunology*

Received date: 9 April 2020

Accepted date: 9 April 2020

Please cite this article as: C.M. Hedrich, COVID-19 – Considerations for the paediatric rheumatologist, *Clinical Immunology* (2020), <https://doi.org/10.1016/j.clim.2020.108420>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.

**COVID-19 – Considerations for the Paediatric Rheumatologist**

Christian M. Hedrich<sup>1,2</sup>

<sup>1</sup> Department of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

<sup>2</sup> Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK

**Correspondence:**

Christian Hedrich, MD, PhD

Institute in the Park, Alder Hey Children's NHS Foundation Trust Hospital  
East Prescott Road, Liverpool, L14 5AB

T +44 151 252 5849

E christian.hedrich@liverpool.ac.uk

**Key words**

COVID, SARS, SARS-CoV2, paediatric, inflammation, ARDS, cytokine storm, rheumatology

**Abstract**

The novel coronavirus SARS-CoV2 is a threat to the health and well-being of millions of lives across the globe. A significant proportion of adult patients require hospitalisation and may develop severe life-threatening complications. Children, on the other hand, can carry and transmit the virus, but usually do not develop severe disease. Mortality in the paediatric age-group is relatively low. Differences in virus containment and clearance, as well as reduced inflammation-related tissue and organ damage may be caused by age-specific environmental and host factors. Since severe complications in adults are frequently caused by uncontrolled immune responses and a resulting “cytokine storm” that may be controlled by targeted blockade of cytokines, previously established treatment with immunosuppressive treatments may indeed protect children from complications.

**Mini Review**

SARS-CoV2 is the pathogen causing COVID-19, a pandemic threatening millions of lives globally. While in most individuals SARS-CoV2 infections are unapparent or associated with mild to moderate symptoms, as many as 10-20% develop severe or life-threatening disease<sup>1</sup>.

Surprisingly for an air-borne viral infection, the number for children diagnosed with COVID-19 is relatively small (2.1% of 42,672 confirmed COVID-19 cases in China were children and young people (<19 years)), and disease-associated mortality among children is low<sup>2,3</sup> (table 1).

Molecular studies targeting the pathophysiology of COVID-19 are sparse, but clinical and molecular parallels with related coronaviruses (SARS-, MERS-CoV) may be extrapolated.

**Infection and immune evasion** -- Both SARS-CoV and SARS-CoV2 use ACE2 as entry receptor facilitating infection. Reflecting common organ involvement, ACE2 is expressed on pulmonary and intestinal epithelial cells<sup>1,4</sup>. As ACE2 is only expressed on a small subset of immune cells, other receptors and/or phagocytosis of virus-containing immune complexes may be involved in their infection<sup>1,5,6</sup>.

SARS-CoV and SARS-CoV2 share the potential to escape the host's immune response<sup>6</sup>. Usually, RNA viruses, including coronaviruses, are detected by endosomal TLR-3 and 7 and/or cytoplasmic RNA sensors RIG-I and MDA5. TLR-3 and 7 promote nuclear shuttling of transcription factors NFκB and IRF3, while RIG-I/MDA5 ligation results in activation of IRF3. This triggers increased expression of type 1 interferons (T1IFN) (through IRF3) and other innate pro-inflammatory cytokines (IL-1, IL-6, TNF-α through NFκB)<sup>6,7</sup>. These induce an "anti-viral state" and innate and adaptive immune responses which contribute to pathogen containment and clearance. Novel coronaviruses can escape these mechanisms by altering ubiquitination and degradation of the RIG-I/MDA5 adaptor molecule mitochondrial antiviral-signalling protein (MAVS), and inhibition of the nuclear translocation of IRF3 and TNF receptor-associated factors (TRAF)3 and 6 which induce NFκB signalling<sup>8</sup>. Furthermore, SARS-CoV and SARS-CoV-2 can counteract T1IFN through inhibition of STAT transcription factor phosphorylation<sup>7</sup>.

**COVID-19 associated cytokine storm** -- Several clinical and laboratory features of COVID-19 are associated with poor outcomes. Early studies from China linked cytopenias (leukopenia, lymphopenia, anaemia, thrombocytopenia) and elevated inflammatory parameters (IL-6, CRP, ESR) with unfavourable outcomes, suggesting cytokine storm syndrome in these patients<sup>9</sup>. ICU dependency in particular was associated with increased plasma levels of innate chemokines IP-10, MIP-1, MIP-1A, and the pro-inflammatory cytokine TNF-α<sup>10</sup>.

Though seemingly contradictory to aforementioned immune evasion through reduced cytokine expression, enhanced innate immune activation promotes morbidity and mortality in COVID-19. However, possible contributors to uncontrolled inflammation are cell damage and death as a result of viral replication<sup>11</sup>. In SARS-CoV infected mice, innate immune cells are recruited to the site of infection, where they induce strong inflammatory responses that further promote tissue damage and systemic inflammation<sup>12</sup>.

Another mechanism contributing to poor outcomes may be antibody-dependent enhancement which is caused by early antibody production. Resulting virus-containing immune complexes promote cellular uptake of virus particles through Fcγ receptors. This may result in persistent viral replication in cells (including antigen-presenting cells), and immune complex mediated inflammation and damage<sup>13-15</sup>. Indeed, blood vessel occlusion

and infarctions have been reported in COVID, and show histopathologic features associated with immune complex vasculitis<sup>12</sup>.

**Why do children not get sicker?** -- Currently, it is not known why children usually develop mild/moderate disease and only rarely develop cytokine storm syndrome (table 1). Several contributors may alter risk in children:

- i) Children are not travelling for business, reducing exposure to people. This may have played a role at the beginning of the pandemic.
- ii) While pathogen clearance may be reduced in adults, particularly in individuals at risk (elderly patients, diabetics, etc.)<sup>6,10</sup>, children have fewer comorbidities, including obesity.
- iii) Different immune response compared to adults, including strong innate and weaker adaptive immune responses. This may contribute to effective virus containment/clearance and/or reduced secondary lymphocyte-mediated inflammation<sup>16</sup>.
- iv) Local microbiomes, co-infections (and co-clearance) with other viruses, and/or immune priming to coronavirus infections as a result of frequent/constant exposure may help children to overcome SARS-CoV2 more effectively.
- v) As ACE2 is essential for epithelial cell infection, but also controls pulmonary inflammation and repair, variable ACE2 expression patterns may affect disease susceptibility and progression<sup>17,18</sup>.

**Risk for patients receiving immunosuppressive treatment** -- Coronaviruses, including SARS-CoV2 are “masters” of immune evasion, which contributes to uncontrolled virus replication and delayed but significant pro-inflammatory cytokine responses. While most children and young people effectively control infections and less frequently develop severe disease, patients receiving immune modulating treatments may have reduced ability to do so. Reassuringly, in a cohort of 200 liver transplant patients on immune suppressive treatment, only three tested positive for SARS-CoV2 and none developed relevant disease<sup>19</sup>.

There are no evidence-based, approved treatments for COVID-19 and/or associated cytokine storm syndromes. Though children receiving immunosuppressive treatment may be at an increased risk for SARS-CoV2 infections, immunosuppression may protect from complications. Antimalarial treatments (chloroquine/hydroxychloroquine) may prevent infection through endocytosis. Classical and/or biologic DMARDs (particularly IL-6 and IL-1 blockers) may control pro-inflammatory cytokine expression and limit tissue/organ damage. Delayed activation of adaptive immune responses may be of benefit, as early antibody production may promote infection of immune cells and/or cause immune complex mediated pathology<sup>15</sup>.

**Conclusions** – While data on COVID-19 is limited, children appear to be protected from severe disease. Paediatric Rheumatology Societies, including the Paediatric Rheumatology European Society (<https://www.pres.eu/news/newsstory.html?id=29>), recognize that discontinuation of immune modulating treatment may result in disease flares. In the absence of symptoms, immune modulating treatment should therefore be continued and

changes should only be made under close monitoring by the responsible clinical service. International collaboration is needed to safely assess individual risk in vulnerable patient groups. Until reliable data is available, close clinical monitoring and social distancing should be prioritized, but the collection of prospective data is required to improve the evidence base.

## References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; **382**(8): 727-33.
2. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. *Clin Chem Lab Med* 2020.
3. Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. *Pediatrics* 2020.
4. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Gorp H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: A first step in understanding SARS pathogenesis. *J Pathol* 2004; **203**(2): 631-7.
5. Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. *Nat Rev Immunol* 2005; **5**(12): 917-27.
6. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemics. *Asian Pac J Allergy Immunol* 2020; **38**(1): 1-9.
7. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. *Nat Rev Microbiol* 2016; **14**(8): 523-34.
8. Kindler E, Thiel V, Weber F. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. *Adv Virus Res* 2016; **96**: 219-43.
9. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020; **395**(10224): 565-74.
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**(10223): 497-506.
11. Atkin-Smith GK, Duan M, Chen W, Poon IKH. The induction and consequences of Influenza A virus-induced cell death. *Cell Death Dis* 2018; **9**(10): 1002.
12. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. *Clin Immunol* 2020; **214**: 108393.
13. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. *Viol Sin* 2020.
14. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. *Rev Med Virol* 2003; **13**(6): 387-98.
15. Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. *Viruses* 2020; **12**(4).
16. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. *Proc Biol Sci* 2015; **282**(1821): 20143085.
17. Uhlen M, Karlsson MJ, Zhong W, et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. *Science* 2019; **366**(6472).
18. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 2005; **436**(7047): 112-6.
19. D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. *Liver Transpl* 2020.

20. Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. *World J Pediatr* 2020.
21. Li Y, Guo F, Cao Y, Li L, Guo Y. Insight into COVID-2019 for pediatricians. *Pediatr Pulmonol* 2020.
22. Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. *Emerg Microbes Infect* 2020; **9**(1): 707-13.
23. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis* 2020.
24. Lin J, Duan J, Tan T, Fu Z, Dai J. The isolation period should be longer: Lesson from a child infected with SARS-CoV-2 in Chongqing, China. *Pediatr Pulmonol* 2020.
25. Zheng F, Liao C, Fan QH, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. *Curr Med Sci* 2020.

Table 1: Disease severity and laboratory findings in children with COVID-19.

Source	Cai et al.	Cai et al.	Chen et al.	Feng et al.	Wanget al.	Zeng et al.	Zhang et al.	Liu et al.	Kam et al.	Chan et al.	Zhang et al.	Zhao et al.	Sun et al. <sup>20</sup>	Li et al. <sup>21</sup>	Su et al. <sup>22</sup>	Qiu et al. <sup>23</sup>	Lin et al. <sup>24</sup>	Zheng et al. <sup>25</sup>	Donget al. <sup>3</sup>	
	Summarised in Henry et al. <sup>2</sup>																		CDC data	
No of cases	10	1	1	15	31	1	1	1	1	1	2	1	8	2	9	36	1	25	2143	
Age (median; range)	6yr (3mo - 11yr)	7yr	13mo	12yr	7yr (6mo - 17yr)	2wk	3mo	7yr	6mo	10yr	14mo (twins)	13yr	5yr (2mo - 15yr)	4yr (4yr)	3.6yr (11mo - 9yr)	8.3 (1-16yr)	7yr	3yr (2-9yr)	7yr (2-13yr)	
Region	China	China	China	China	China	China	China	China	Singapore	China	China	China	China	China	China	China	China	China	China	
Males	4 (40%)	1 (100%)	1 (100%)	5 (33%)	15 (48%)	1 (100%)	0	1 (100%)	1 (100%)	1 (100%)	0	1 (100%)	6 (75%)	1 (500%)	3 (33%)	23 (64%)	0	14 (56%)	1213 (56.6%)	
Symptoms	10 (100%), mild	1 (100%), mild	1 (100%), mild	3 (20%), mild	27 (87%), mild	1 (100%), mild	1 (100%), mild	1 (100%), mild	0	0	2 (100%), mild	1 (100%), mild	<b>8 (100%), severe or critical</b>	2 (100%), moderate	3 (33%), mild to moderate	36 (100%), 17 (47.2%) mild, 19 (52.8%) moderate	1 (100%), mild	25 (100%), 8 (32) mild, 15 (60%) moderate, 2 (8%) severe	2047 (94.9%), 1091 (50.9%) mild, 831 (38.8%) moderate, 112 (5.2%) severe, 13 (0.6%) critical	
Chest radiographic changes	4 (40%)	1 (100%)	1 (100%)	9 (60%)	14 (45%)	1 (100%)	1 (100%)	1 (100%)	0	1 (100%)	1 (50%)	1 (100%)	8 (100%)	2 (100%)	5 (55.5%)	19 (53%), all in moderate disease	0	17 (68%)	N/A	
WBC ↑	3 (30%)	1 (100%)	1 (100%)	0	3 (9.7%)	0	0	0	0	0	2 (100%)	0	2 (25%)	0	0	0	0	0	0	N/A
WBC ↓	1 (10%)	0	0	7 (15%)	2 (6.5%)	0	0	0	1 (100%)	0	0	0	1 (12.5%)	0	3 (33%)	7 (19.4%)	0	0	0	N/A
Lymphocytes ↑	1 (10%) ↑	N/A	1 (100%)	N/A	4 (12.9%)	N/A	N/A	0	0	0	N/A	0	0	0	0	11 (30.5%) ↓	0	0	0	N/A
Lymphocytes ↓	0	N/A	0	N/A	2 (6.5%)	N/A	N/A	0	1 (100%)	0	0	0	1 (12.5%)	0	0	0	0	0	0	N/A
HB ↓	0	N/A	1 (100%)	N/A	N/A	0	0	N/A	N/A	0	0	0	3 (37.5%)	N/A	5 (55%)	N/A	0	N/A	N/A	N/A



			%)										%)	)					
<b>PLT</b> ↑	2 (20%)	0	0	N/A	2 (6.5%)	1 (100%)	1 (100%)	0	0	0	2 (100%)	0	2 (25%)	N/A	0	N/A	0	N/A	N/A
<b>PLT</b> ↓	1(10%)	1 (100%)	0	N/A	0	0	0	0	1 (100%)	0	0	0	1 (12.5%)	N/A	1 (11%)		0		
<b>CRP</b> ↑	3 (30%)	1 (100%)	1 (100%)	N/A	3 (9.7%), N/A for 1 (3.2%)	0	0	0	N/A	0	1 (50%)	0	5 (62.5%)	1 (50%)	0	1 (2.0%)	0	N/A, medi an 14.5 mg/L 0.91- 25.0 4) (Nor mal: <10 ml/L)	N/A
<b>ESR</b> ↑	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0	N/A	N/A	0	0	N/A	N/A	N/A
<b>LFT</b> ↑	2 (20%)	0	N/A	N/A	7 (22%)	N/A	N/A	0	N/A	0	2 (100%)	0	3 (37.5%)	0	0	3 (8.3%)	0	0	N/A

Currently available datasets are from Chinese cohorts. Most children experienced mild or moderate disease, while 133 of 2290 children summarised in table 1 were severely or critically ill (**bold italics**) (5.8%), and 2 died (0.09%). Few children who developed severe COVID-19 did not consistently exhibit clinical and/or laboratory signs of cytokine storm syndromes, such as cytopenias, or altered liver function. While data are very limited, this appears to be in contrast to adult cohorts, where significant proportions of severely ill patients show signs of cytokine storm syndrome, which is associated with poor outcomes<sup>1,9</sup>. **Abbreviations:** WBC: white blood counts, HB: haemoglobin, PLT: Platelet counts, CRP: C reactive protein, ESR: erythrocyte sedimentation rate, LFT: liver function tests (AST and/or ALT elevation), N/A: not available.

**Highlights**

- The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions of lives globally
- Children with COVID-19 rarely develop severe symptoms and mortality is relatively low
- Co-infections (and co-clearance) with other viruses may help children to overcome SARS-CoV2
- Fewer comorbidities and age-specific host factors may protect children
- Limited experience suggests that pre-existing anti-inflammatory treatment may not increase risk significantly

Journal Pre-proof